Literature DB >> 26190680

Metabolomics in the pharmaceutical industry.

Michael D Reily1, Adrienne A Tymiak2.   

Abstract

Metabolomics has roots in the pharmaceutical industry that go back nearly three decades. Initially focused on applications in toxicology and disease pathology, more recent academic and commercial efforts have helped advance metabolomics as a tool to reveal the molecular basis of biological processes and pharmacological responses to drugs. This article will discuss areas where metabolomic technologies and applications are poised to have the greatest impact in the discovery and development of pharmaceuticals.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Mesh:

Year:  2015        PMID: 26190680     DOI: 10.1016/j.ddtec.2015.03.001

Source DB:  PubMed          Journal:  Drug Discov Today Technol        ISSN: 1740-6749


  8 in total

1.  Safety assessment of cosmetics by read across applied to metabolomics data of in vitro skin and liver models.

Authors:  Carine Jacques; Emilien L Jamin; Isabelle Jouanin; Cécile Canlet; Marie Tremblay-Franco; Jean-François Martin; Daniel Zalko; Yves Brunel; Sandrine Bessou-Touya; Laurent Debrauwer; Pierre-Jacques Ferret; Hélène Duplan
Journal:  Arch Toxicol       Date:  2021-08-30       Impact factor: 5.153

Review 2.  The metabolic role of the gut microbiota in health and rheumatic disease: mechanisms and interventions.

Authors:  Shahla Abdollahi-Roodsaz; Steven B Abramson; Jose U Scher
Journal:  Nat Rev Rheumatol       Date:  2016-06-03       Impact factor: 20.543

Review 3.  Metabolomics: Bridging the Gap between Pharmaceutical Development and Population Health.

Authors:  Vladimir Tolstikov
Journal:  Metabolites       Date:  2016-07-08

4.  Therapeutic Effects of Chinese Medicine Herb Pair, Huzhang and Guizhi, on Monosodium Urate Crystal-Induced Gouty Arthritis in Rats Revealed by Anti-Inflammatory Assessments and NMR-Based Metabonomics.

Authors:  Bin Han; Huizhu Huang; Zhong Li; Mengjuan Gong; Wan Shi; Chunxia Zhu; Zulian Gu; Zhongjie Zou
Journal:  Evid Based Complement Alternat Med       Date:  2016-02-16       Impact factor: 2.629

Review 5.  "Omics"-Informed Drug and Biomarker Discovery: Opportunities, Challenges and Future Perspectives.

Authors:  Holly Matthews; James Hanison; Niroshini Nirmalan
Journal:  Proteomes       Date:  2016-09-12

6.  Impact of novel palmitoylated prolactin-releasing peptide analogs on metabolic changes in mice with diet-induced obesity.

Authors:  Veronika Pražienková; Martina Holubová; Helena Pelantová; Martina Bugáňová; Zdenko Pirník; Barbora Mikulášková; Andrea Popelová; Miroslava Blechová; Martin Haluzík; Blanka Železná; Marek Kuzma; Jaroslav Kuneš; Lenka Maletínská
Journal:  PLoS One       Date:  2017-08-18       Impact factor: 3.240

7.  Breaking the cycle: Reversal of flux in the tricarboxylic acid cycle by dimethyl fumarate.

Authors:  Arie R Gafson; Constantinos Savva; Tom Thorne; Mark David; Maria Gomez-Romero; Matthew R Lewis; Richard Nicholas; Amanda Heslegrave; Henrik Zetterberg; Paul M Matthews
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-04-22

8.  Prediction of liver toxicity and mode of action using metabolomics in vitro in HepG2 cells.

Authors:  Tzutzuy Ramirez; Alexander Strigun; Andreas Verlohner; Hans-Albrecht Huener; Erik Peter; Michael Herold; Natalie Bordag; Werner Mellert; Tilmann Walk; Michael Spitzer; Xiaoqi Jiang; Saskia Sperber; Thomas Hofmann; Thomas Hartung; Hennicke Kamp; Ben van Ravenzwaay
Journal:  Arch Toxicol       Date:  2017-09-30       Impact factor: 5.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.